Two Presentation Offprints on the Foundations of Chemotherapy
1907 and 1909. First Edition. Ehrlich received the Nobel Prize in Physiology or Medicine in 1908, shared with Élie Metchnikoff, for his work on immunity; yet the research by which his name entered most consequentially into the practice of modern medicine lies in the chemotherapeutic program documented in these two papers. Every antibiotic prescription written today, every drug resistance protocol followed in a hospital, every combination therapy deployed against HIV, tuberculosis, or drug-resistant malaria traces its conceptual lineage to the framework Ehrlich developed here. Working from trypanosome infections in laboratory animals, he was the first to formulate with full theoretical self-consciousness the idea that treatment could become a rational science: the deliberate identification of chemically defined substances capable of destroying a pathogen selectively while sparing the host. In doing so, he brought into a single experimental and conceptual framework problems that still define anti-infective medicine today — selective toxicity, the relation between chemical constitution and biological effect, the emergence of acquired drug resistance under therapeutic pressure, and the need to meet that resistance by systematic testing, therapeutic comparison, and, where necessary, combined treatment. The program advanced in these offprints culminated later in 1909 in Ehrlich's announcement of Salvarsan, the first widely recognized modern chemotherapeutic agent, and from that point runs a continuous historical line through the sulfonamides and antibiotics to the broader ideal of targeted therapy itself. Both copies are presentation copies, inscribed by Ehrlich to leading figures in parasitology and pathology on two continents, and both are rare in institutional or private hands outside Germany. Item #1298
"Chemotherapeutische Trypanosomen-Studien; from Sonderabdruck aus der Berliner klinische Wochenschrift, no. 9-12." Berlin: L. Schumacher, 1907. Offprint, 8vo (221 x 146mm), pp. 42. Original printed wrappers, staple-bound, toned, spine chipped with small chips along the extremities, notations on the front cover and first page, stamp of Georgre Nuttall and University of Cambridge, else very good. Presentation copy, inscribed to George Nuttall.
A lecture delivered before the Berliner medizinischen Gesellschaft on 13 February 1907, in which Ehrlich surveys the results of animal experimentation with large numbers of synthetic compounds against trypanosome infections and argues that only exhaustive comparative testing can identify agents suitable for therapeutic use. He defines the goal as a "Chemotherapia specifica" (the selective destruction of parasites with minimal host injury) and formulates this relation in terms of stronger "ätiotrope" than "organotrope" drug action, offering not merely a report on particular compounds but a theoretical framework linking chemical constitution, biological distribution, parasite affinity, and therapeutic efficacy. The paper is equally notable for its treatment of resistance: Ehrlich describes the emergence of atoxyl-resistant trypanosome strains under treatment, considers the implications for therapeutic failure, and recommends laboratory testing of resistant isolates together with a shift toward combination therapy when single-agent treatment fails; anticipating principles of selective toxicity, resistance surveillance, and combination treatment that remain central to anti-infective pharmacology. The recipient, George Henry Falkiner Nuttall, was parasitologist and Quick Professor of Biology at Cambridge and founder of the journal Parasitology; his collection passed to the Molteno Institute for Research in Parasitology at Cambridge, whose stamp appears on the title page alongside Ehrlich's inscription.
"Ueber die neuesten Ergebnisse auf dem Gebiete der Trypanosomenforschung; from Sonder-Abdruck aus Archiv für Schiffs- und Tropenhygiene, Band XIII, Beiheft 6, pp. 91-116." Leipzig: Johann Ambrosius Barth, 1909. Offprint, 8vo (235 x 160mm), pp. 26. Orginal green printed wrappers, binder holes punched along the spine, library call number stamp to the front wrapper, lightly toned, some soft creases, else very good. Inscribed to William MacCallum.
A lecture delivered on 7 April 1909 before the Deutsche tropenmedizinische Gesellschaft in Berlin, reporting the results of collaborative trypanosome research conducted with Shiga, Franke, Browning, Röhl, Gulbransen, and others at the Institut für experimentelle Therapie in Frankfurt. The paper is organized around two interconnected problems: the mechanism of drug resistance and the receptor-based theory of drug action. Ehrlich explains resistance through the concept of Chemozeptoren (specific chemical groupings in the trypanosome with particular affinity for given drug radicals) whose progressive reduction in avidity under therapeutic pressure accounts for the gradual acquisition of resistance, and draws a sharp mechanistic distinction between drug-resistant strains, which develop gradually through successive reductions in receptor avidity, and serum-resistant strains, which arise suddenly through a process Ehrlich characterizes as mutation, involving the disappearance of a specific Nutrizeptor and the emergence of an entirely new receptor type. He then develops the theory of Arsenozeptoren in detail, distinguishing compounds such as atoxyl and arsazetin (which kill trypanosomes in vivo but not in vitro) from trivalent arsenical derivatives whose in vitro trypanocidal activity he reports at extreme dilutions, explaining atoxyl's therapeutic activity through its in vivo reduction to trivalent arsenic. The lecture closes with a discussion of arsenophenylglyzin as the most promising compound yet identified in animal trials and articulates the goal of a Therapia sterilisans (complete sterilization of the organism in a single treatment) recommending that clinical trials in sleeping sickness be conducted first on fresh, previously untreated cases. The paper is directly antecedent to Ehrlich's announcement of Salvarsan later the same year. The recipient, William George MacCallum, was professor of pathology at Johns Hopkins whose early discovery of the sexual cycle of the malarial parasite had established his reputation at the intersection of pathology and parasitology.
Price: $10,000.00